Pancreatic cancer is one of the most prothrombotic malignancies. Plasma clot properties may be altered in patients with pancreatic cancer, and circulating tissue factor (TF) may play an important role. We applied a modified plasma clot formation assay (only CaCl2and phospholipids were added to initiate clotting) and a standard clotting assay (lipidated TF was also added) to investigate whether plasma clot properties are altered in pancreatic cancer patients (n = 40, 23 female) compared to sex-matched healthy controls. The modified assay was also performed in the presence of a TF blocking antibody. With this modified assay, we detected an increased plasma clot formation rate (Vmax) and an increased delta absorbance (ΔAbs, indicating fibrin fiber thickness) in patients compared to controls. These differences were not detected with the standard clotting assay. Following addition of a TF blocking antibody in in our modified assay, Vmax decreased significantly in patients only, ΔAbs significantly decreased in patients and in healthy controls, the lag phase did not change, and the time to peak fibrin generation increased in patients only. Taken together, these findings indicate the presence of a prothrombotic state in pancreatic cancer patients, which depends on TF and is detectable with our modified assay but not with a standard clotting assay.
胰腺癌是最易形成血栓的恶性肿瘤之一。胰腺癌患者的血浆凝块特性可能发生改变，而循环组织因子（TF）可能在其中起重要作用。我们采用改良的血浆凝块形成试验（仅加入CaCl₂和磷脂以启动凝血）和标准凝血试验（额外加入脂化组织因子），旨在探究胰腺癌患者（n=40，23名女性）与性别匹配的健康对照组相比，其血浆凝块特性是否发生改变。改良试验还在加入组织因子阻断抗体条件下进行。通过改良试验，我们发现患者组较对照组的血浆凝块形成速率（Vmax）和吸光度变化值（ΔAbs，反映纤维蛋白纤维厚度）均显著升高，而这些差异在标准凝血试验中未被检测到。在改良试验中加入组织因子阻断抗体后，仅患者组的Vmax显著下降；患者组和健康对照组的ΔAbs均显著降低；滞后阶段无变化；仅患者组的纤维蛋白生成达峰时间延长。综上所述，这些结果表明胰腺癌患者存在易栓状态，该状态依赖于组织因子，可通过我们的改良试验检测，但无法通过标准凝血试验发现。
肿瘤(癌症)患者之家